High cholinesterase predicts tolerance to sorafenib treatment and improved prognosis in patients with transarterial chemoembolization refractory intermediate stage hepatocellular carcinoma

Takaki,Shintaro; Fukuhara,Takayuki; Mori,Nami; Tsuji,Keiji

doi:10.3892/mco.2019.1949

High cholinesterase predicts tolerance to sorafenib treatment and improved prognosis in patients with transarterial chemoembolization refractory intermediate stage hepatocellular carcinoma

Authors:
- Shintaro Takaki
- Takayuki Fukuhara
- Nami Mori
- Keiji Tsuji
View Affiliations

Affiliations: Department of Gastroenterology, Hiroshima Red Cross Hospital and Atomic‑Bomb Survivors Hospital, Hiroshima 730‑8619, Japan
Published online on: November 18, 2019 https://doi.org/10.3892/mco.2019.1949
Pages: 60-68

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although sorafenib is the standard treatment for patients with advanced hepatocellular carcinoma (HCC), the predictive factors sorafenib tolerance in intermediate‑stage HCC cannot be accurately determined. The aim of the current study was to identify the predictive characteristics for the continuation of sorafenib treatment (≥400 mg) in patients with transarterial chemoembolization (TACE)‑refractory intermediate HCC and to identify candidates for second‑line sorafenib treatment. A total of 33 TACE‑refractory intermediate patients with HCC that were treated with sorafenib, and who had reached progressive disease (PD), were analyzed in the present retrospective study. Of 33 patients, 6 patients (18.1%) were able to continue sorafenib treatment (≥400 mg) until PD, however, a total of 27 patients (71.9%) were unable to continue treatment (<400 mg). The current study compared the baseline characteristics parameters to sorafenib ≥400 mg and <400 mg using a logistic regression model. The overall survival (OS) of patients receiving sorafenib ≥400 mg treatment was significantly increased compared with patients receiving sorafenib treatment <400 mg [554.5 days (228‑674) vs. 219 days (134‑369); P=0.0315). A univariate analysis was performed and indicated that Age (<75 years; P=0.021), total cholesterol (>180 mg/dl; P=0.026) and cholinesterase (ChE; ≥220 U/l; P=0.024) were significant factors, and a multivariate analysis indicated that ChE (≥220 U/l) was a significant prognostic factor (HR: 11.9; 95% CI: 1.19‑118.0; P=0.004). Both progression‑free survival [279 (204‑403) vs. 117.5 (63‑197) days; P=0.0136] and OS [470 (277‑679) vs. 171.5 (80‑236) days; P=0.0004] were significantly increased in patients with ChE levels ≥220 U/l compared with patients exhibiting ChE levels <220 U/l. Baseline high value of ChE in intermediate‑stage HCC predicts the ability to continue sorafenib treatment at ≥400 mg.

View Figures

View References

1	Bruix J, Gores GJ and Mazzaferro V: Hepatocellular carcinoma: Clinical frontiers and perspectives. Gut. 63:844–855. 2014. View Article : Google Scholar : PubMed/NCBI
2	Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
3	Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Lu R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of sorafenib in patients in the asia-pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar : PubMed/NCBI
4	Ikeda M, Mitsunaga S, Shimizu S, Ohno I, Takahashi H, Okuyama H, Kuwahara A, Kondo S, Morizane C, Ueno H, et al: Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. J Gastroenterol. 49:932–940. 2014. View Article : Google Scholar : PubMed/NCBI
5	Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Motoyama T, Suzuki E, Tawada A, Kanai F, Yoshikawa M and Yokosuka O: Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization. Oncology. 87:330–341. 2014. View Article : Google Scholar : PubMed/NCBI
6	Arizumi T, Ueshima K, Minami T, Kono M, Chishina H, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, et al: Effectiveness of sorafenib in patients with transcatheter arterial chemoembolization (TACE) refractory and intermediate-stage hepatocellular carcinoma. Liver Cancer. 4:253–262. 2015. View Article : Google Scholar : PubMed/NCBI
7	Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, Takayama T, Yoon JH, Hori T, Kumada H, Hayashi N, et al: Phase III study of sorafenib after transarterial chemoembolization in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer. 47:2117–2127. 2011. View Article : Google Scholar : PubMed/NCBI
8	Lencioni R, Llovet JM, Han G, Tak WY, Yang J, Guglielmi A, Paik SW, Reig M, Kim DY, Chau GY, et al: Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. J Hepatol. 64:1090–1098. 2016. View Article : Google Scholar : PubMed/NCBI
9	Ohki T, Sato K, Yamagami M, Ito D, Yamada T, Kawanishi K, Kojima K, Seki M, Toda N and Tagawa K: Efficacy of transcatheter arterial chemoembolization followed by sorafenib for intermediate/advanced hepatocellular carcinoma in patients in Japan: A retrospective analysis. Clin Drug Investig. 35:751–759. 2015. View Article : Google Scholar : PubMed/NCBI
10	Ohki T, Sato K, Yamagami M, Ito D, Yamada T, Kawanishi K, Kojima K, Seki M, Toda N and Tagawa K: Erratum to: Efficacy of transcatheter arterial chemoembolization followed by sorafenib for intermediate/advanced hepatocellular carcinoma in patients in Japan: A retrospective analysis. Clin Drug Investig. 36:93–96. 2016. View Article : Google Scholar : PubMed/NCBI
11	Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, et al: Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 389:56–66. 2017. View Article : Google Scholar : PubMed/NCBI
12	Ogasawara S, Chiba T, Ooka Y, Suzuki E, Maeda T, Yokoyama M, Wakamatsu T, Inoue M, Saito T, Kobayashi K, et al: Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment. Invest New Drugs. 36:332–339. 2018. View Article : Google Scholar : PubMed/NCBI
13	Lencioni R and Llovet JM: Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 30:52–60. 2010. View Article : Google Scholar : PubMed/NCBI
14	Uchikawa S, Kawaoka T, Aikata H, Kodama K, Nishida Y, Inagaki Y, Hatooka M, Morio K, Nakahara T, Murakami E, et al: Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice. Hepatol Res. 48:814–820. 2018. View Article : Google Scholar : PubMed/NCBI
15	Kuzuya T, Ishigami M, Ishizu Y, Honda T, Hayashi K, Ishikawa T, Nakano I, Hirooka Y and Goto H: Prognostic factors associated with postprogression survival in advanced hepatocellular carcinoma patients treated with sorafenib not eligible for second-line regorafenib treatment. Oncology. 95:91–99. 2018. View Article : Google Scholar : PubMed/NCBI
16	Kanda Y: Investigation of freely-available easy-to use software ‘EZR’ for medial statistics. Bone Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
17	The general rules for the clinical and pathological study of primary liver cancer study group of japan. Liver cancer study group of Japan. Jpn J Surg. 19:98–129. 1989. View Article : Google Scholar : PubMed/NCBI
18	Takeda H, Nishikawa H, Iguchi E, Ohara Y, Sakamoto A, Hatamaru K, Henmi S, Saito S, Nasu A, Komekado H, et al: Impact of pretreatment cholinesterase level in unresectable advanced hepatocellular carcinoma patients treated with sorafenib. Mol Clin Oncol. 1:241–248. 2013. View Article : Google Scholar : PubMed/NCBI
19	European association for the study of the liver electronic address, . simpleEasloffice@easloffice.eu; European association for the study of the liver: EASL clinical practice guideline: Management of hepatocellular carcinoma. J Hepatol. 69:182–236. 2018. View Article : Google Scholar : PubMed/NCBI
20	Brux J and Shernman M; American association for the study of liver disease, : Management of hepatocellular carcinoma: An update. Hepatology. 53:1020–1022. 2011. View Article : Google Scholar : PubMed/NCBI
21	Heimbach JK, Kulil LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, Zhu AX, Murad MH and Marrero JA: AASLD guidelines for treatment of hepatocellular carcinoma. Hepatology. 67:358–380. 2018. View Article : Google Scholar : PubMed/NCBI
22	Verslype C, Rosmorduc O and Rougier P; ESMO Guidelines Working Group, : Hepatocellular carcinoma: ESMO-ESDO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 23 (Suppl 7):vii41–vii48. 2012. View Article : Google Scholar : PubMed/NCBI
23	Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y, Okusaka T, Miyayama S, Tsuchiya K, Ueshima K, et al: JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the liver cancer study group of Japan. Liver Cancer. 3:458–468. 2014. View Article : Google Scholar : PubMed/NCBI
24	Terashima T, Yamashita T, Horii R, Arai K, Kawaguchi K, Kitamura K, Yamashita T, Sakai Y, Mizukoshi E, Honda M and Kaneko S: Potential efficacy of therapies targeting intrahepatic lesions after sorafenib treatment of patients with hepatocellular carcinoma. BMC Cancer. 31:3382016. View Article : Google Scholar
25	Wada Y, Takami Y, Tateishi M, Ryu T, Mikagi K and Saitsu H: The efficacy of continued sorafenib treatment after radiologic confirmation of progressive disease in patients with advanced hepatocellular carcinoma. PLoS One. 11:e01464562016. View Article : Google Scholar : PubMed/NCBI
26	Fu SR, Zhang YQ, Hu BS, He X, Huang JW, Zhan MX, Lu LG and Li JP: Sorafenib continuation after first disease progression could reduce disease flares and provide survival benefits in patients with hepatocellular carcinoma: A pilot retrospective study. Asian Pac J Cancer Prev. 15:3151–3156. 2014. View Article : Google Scholar : PubMed/NCBI